ORPN - Bioblast Pharma Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
11.50
+0.72 (+1.31%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close11.20
Open11.15
Bid0.00 x 800
Ask0.00 x 800
Day's Range10.81 - 11.74
52 Week Range10.81 - 11.74
Volume10,152
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Bioblast Announces Effectiveness of Eight to One Reverse Split

    Bioblast Pharma Ltd. (ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to one reverse split of its share capital. Bioblast previously announced the execution of a definitive merger agreement to acquire Enlivex Therapeutics Ltd., a privately-held immunotherapy company.

  • ACCESSWIRE

    4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)

    CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. As a result of the advent of new technologies and product offerings in other industries, healthcare customers have come to expect the same experience from healthcare companies. ), AcelRx Pharmaceuticals Inc (ACRX), and Bio Blast Pharma Ltd (ORPN) represent four healthcare companies operating with the consumer's best interests in mind.

  • GlobeNewswire

    Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, announced today a definitive agreement with Bioblast Pharma Ltd., (ORPN), whereby Seelos acquired all development and commercial rights to Bioblast’s proprietary trehalose 90 mg/mL IV (Trehalose) solution as well as the existing inventory of the drug which should be sufficient to fulfill its current research needs. Trehalose, which is currently an investigational molecule, has been studied in prior phase 2 clinical studies in over 70 patients with two rare diseases and demonstrated a favorable safety profile and promising efficacy signal.

  • GlobeNewswire

    Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics

    Bioblast Pharma Ltd. (ORPN),  a clinical-stage, orphan disease-focused biotechnology company, today announced the sale of its Trehalose clinical development programs (including its advanced phase 2 clinical program of Trehalose to treat Oculoharyngeal Muscular Dystrophy (OPMD) to Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company. $1.5 million payable upon closing of the sale and the other $2.0 million will be paid upon the first anniversary of the closing of the sale.  Potential additional milestone payments of up to $17.0 million will be made upon completion of the clinical study and approval of a New Drug Application (NDA) by the Food and Drug Administration (FDA), as well as royalties.

  • GlobeNewswire

    Bioblast Pharma Announces Collaboration with Team Sanfilippo to Evaluate Trehalose for the Treatment of Sanfilippo Syndrome

    Bioblast Pharma Ltd. (ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome today announced a clinical collaboration to evaluate the safety and efficacy of Bioblast’s proprietary Trehalose solution for the treatment of patients with Sanfilippo syndrome. Under the terms of the collaboration, TSF plans to conduct an open label study in up to 20 Sanfilippo patients, which will be followed for safety and efficacy.

  • GlobeNewswire

    Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance

    Bioblast Pharma Ltd. (ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that Nasdaq has determined that Bioblast’s stockholders’ equity does not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1).

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: Auris Medical and Bioblast Pharma

    NEW YORK, NY / ACCESSWIRE / November 21, 2018 / It was a day of gains for biotech stocks Auris Medical Holding and Bioblast Pharma after the companies announced positive developments. Bioblast announced it has executed a definitive agreement to acquire Enlivex Therapeutics while Auris Medical announced the results of a Pre-IND meeting with the FDA. Auris Medical Holding AG shares were up nearly 36% on Tuesday on roughly 13.7 million shares traded.

  • ACCESSWIRE

    New Healthcare Trends Have Investors Looking at 4 Stocks

    Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.

  • GlobeNewswire

    Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors

    Enlivex is developing a novel immunotherapy with a unique mode of action targeting clinical indications defined as “life-threatening, unmet medical need,” such as preventing or treating complications associated with bone-marrow transplantations, sepsis – which is the third-leading cause of mortality in the U.S. after cardiovascular and cancer diseases, as well as effective treatment of solid tumors via immune checkpoint reprogramming, increasing the efficacy of CAR-T, TCR and other anti-cancer therapies. Phase IIa clinical trial for the prevention of GvHD in matched-donor population successfully completed.  Initiation of Phase II clinical trial in sepsis expected in Q2-2019, and initiation of a Phase II clinical trial for treatment of steroid-refractory GvHD patients and a Phase II/III clinical trial for preventing GvHD in bone marrow transplantations are expected in Q4-2019.